Company from Germany CureVac allowed testing of vaccines against coronavirus infection COVID-19 in Germany and Belgium. About it reports a press-service of the company.
“Joint-stock company CureVac, a biopharmaceutical company and a pioneer in the field of preclinical and clinical development of medicines based on mRNA, today announced that the German regulator, the Paul Ehrlich Institute (PEI) and the Belgian Federal Agency of medicine and products in the field of health (FAMHP) has approved the study clinical phase 1 program of vaccination to prevent infection SARS-CoV-2”, – said the company.
Research will be carried out in tübingen at the Institute of tropical medicine, University hospital of Munich, graduate school of medicine in Hanover and at the University hospital of Ghent (Belgium).
The project CureVac’s vaccine started in early 2020. In the first preclinical phase will be grafted 168 people aged 18 to 60 years.
On 14 June it was reported that Germany, Italy, France and the Netherlands signed an agreement to purchase up to 400 million doses of vaccines from COVID-19 for member countries of the European Union. Contract partner is the pharmaceutical company AstraZeneca.
Who believe that the coronavirus would pose a serious threat, until they invent a vaccine. According to the head of the European Agency of medicines Marco Kavaleri, in the best case, the vaccine will be ready next year.
Flash coronavirus infection COVID-19 began in late 2019 in China. March 11, 2020, the world health organization declared the spread of the coronavirus pandemic.